Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This phase II clinical trial evaluates the efficacy, safety and tolerability of Atezolizumab in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Written informed consent
Patients with locally advanced or metastatic large-cell neuroendocrine carcinoma of the lung (LCNEC) without curative treatment options (patients with mixed histology are eligible if LCNEC is the predominant histology i.e. ≥50%)
Previously untreated with systemic therapy (note: patients relapsing after curative radio chemotherapy or adjuvant chemotherapy are eligible if relapse occurs ≥6 months after discontinuation of curative treatment)
Planned treatment with Carboplatin or Cisplatin and Etoposide (SoC)
ECOG performance status: 0-2
age ≥18 years
measurable disease according to RECIST v1.1
adequate organ function defined as:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
67 participants in 1 patient group
Loading...
Central trial contact
Martin Wermke, MD; Felix C Saalfeld, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal